|
Apr 24
|
Faron Announces Acceptance of Bexmarilimab Phase II Data for Oral Presentation at ASCO 2025
|
|
Jan 9
|
Inside information: Faron Announces First HMA-failed MDS Patient Dosed with Bexmarilimab as part of Phase 2 of BEXMAB Trial
|
|
Dec 7
|
Faron Announces Publication of Full Analysis from Phase 1/2 MATINS Trial of Bexmarilimab in Solid Tumors in Cell Reports Medicine
|